00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
00:33 , Jan 25, 2019 |  BC Week In Review  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18 by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
00:30 , Jan 19, 2019 |  BC Extra  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
16:02 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Nektar makes case for NKTR-214 optimism

On a Nov. 10 call with investors, Nektar Therapeutics (NASDAQ:NKTR) and a PI for the Phase I/II PIVOT-2 trial highlighted differences in patient demographics that could be critical for NKTR-214 plus Opdivo nivolumab to achieve...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
21:18 , Nov 12, 2018 |  BC Extra  |  Clinical News

Nektar makes case for NKTR-214 optimism

On a call with investors Saturday, Nektar Therapeutics (NASDAQ:NKTR) and a PI for the Phase I/II PIVOT-2 trial highlighted differences in patient demographics that could be critical for NKTR-214 plus Opdivo nivolumab to achieve a...
16:47 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. Merck...
01:10 , Oct 22, 2018 |  BC Extra  |  Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. This...